Regeneron Pharmaceuticals REGN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.61B+19.0% | $3.88B+2.5% | $3.75B+0.9% | $3.68B+3.6% | $3.03B-3.7% | ||
| —— | —— | —— | —— | —— | ||
| $1.54B+16.3% | $1.63B+15.2% | $1.48B+16.0% | $1.42B+18.5% | $1.33B+6.3% | ||
| $647.7M+2.3% | $775M-2.2% | $657.8M-7.9% | $634.2M-16.4% | $633M-8.1% | ||
| $2.96B+21.6% | $3B+7.3% | $2.73B+7.3% | $2.6B+4.8% | $2.44B+1.8% | ||
| $642.9M+8.7% | $879.9M-11.1% | $1.03B-12.9% | $1.08B+0.9% | $591.7M-21.3% | ||
| 17.8%-1.7pp | 22.7%-3.5pp | 27.3%-4.4pp | 29.4%-0.8pp | 19.5%-4.4pp | ||
| $12.9M+48.3% | $12.2M+16.2% | $19.3M+39.9% | $3.6M-75.7% | $8.7M-46.0% | ||
| $188.3M-39.9% | $163.8M— | $736.5M+135% | $439.2M-21.4% | $313.3M+718% | ||
| $831.2M-8.2% | $1.04B+8.9% | $1.76B+18.1% | $1.52B-6.7% | $905M+29.2% | ||
| $104M+8.0% | $199.1M+393% | $303.3M+99.0% | $127.1M-35.1% | $96.3M+552% | ||
| $727.2M-10.1% | $844.6M-8.0% | $1.46B+8.9% | $1.39B-2.8% | $808.7M+12.0% | ||
| 20.2%-6.5pp | 21.7%-2.5pp | 38.9%+2.9pp | 37.9%-2.5pp | 26.7%+3.7pp | ||
| $6.75-7.2% | $7.87-3.0% | $13.62+18.0% | $12.81+3.2% | $7.27+15.9% | ||
| $6.99-7.8% | $8.24-3.5% | $14.09+13.6% | $13.24-0.1% | $7.58+13.1% | ||
| 107.7M-3.1% | 108.6M-5.6% | 107.2M-7.7% | 108.6M-5.9% | 111.2M-3.4% | ||
| 104M-2.5% | 104.6M-3.1% | 103.6M-4.2% | 105.1M-2.8% | 106.7M-1.0% | ||
| $101.9M+728% | $18.7M+35.5% | $83.1M+47.9% | $10M-58.2% | $12.3M+73.2% | ||
| $661.6M-21.8% | $853.1M+0.4% | $1.48B+0.4% | $1.42B-1.7% | $845.7M+16.5% | ||
| -$65.8M-273% | $7.1M— | $15.7M-87.8% | $22.1M+180% | $38.1M+989% | ||
| $201.2M-37.5% | $176M— | $755.8M+131% | $442.8M-22.8% | $322M+1,031% | ||
| $3.61B+19.0% | $3.88B+2.5% | $3.75B+0.9% | $3.68B+3.6% | $3.03B-3.7% | ||
| $766.1M+6.6% | $1.02B-8.2% | $1.16B-10.6% | $1.21B+2.0% | $718.6M-17.0% | ||
| 21.2%-2.5pp | 26.4%-3.1pp | 31%-4.0pp | 33%-0.5pp | 23.7%-3.8pp | ||
| $642.9M+8.7% | $879.9M-11.1% | $1.03B-12.9% | $1.08B+0.9% | $591.7M-21.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Regeneron Pharmaceuticals's revenue?
- Regeneron Pharmaceuticals (REGN) generated $14.9B in revenue over the trailing twelve months, up 5.9% year over year.
- Is Regeneron Pharmaceuticals profitable?
- Regeneron Pharmaceuticals reported $4.4B in net income over the trailing twelve months, a 29.6% net margin.
- What are Regeneron Pharmaceuticals's profit margins?
- Gross margin is 93.9% and operating margin is 24.3%, with a 29.6% net margin.
- What is Regeneron Pharmaceuticals's earnings per share?
- Regeneron Pharmaceuticals's diluted EPS over the trailing twelve months is $41.05.
- Where does Regeneron Pharmaceuticals's income statement data come from?
- Every line is extracted from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
